StockData
CG Oncology, Inc. logo

CG Oncology, Inc. (CGON) stock

CGONNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 6, 2026Score 5/30
$78.94−5.84 (-6.89%)

Close on Nov 17, 2026Market cap $7.00BP/E –Yield –

CG Oncology operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

CG Oncology's operating cash flow for the twelve months ending Sep 30, 2026 was -$187.28M. For fiscal 2025 it was -$132.35M.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$132.35M–
FY2024Dec 31, 2024-$78.71M–
FY2023Dec 31, 2023-$45.68M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$47.71M–
Q2 FY2026Jun 30, 2026-$46.41M–
Q1 FY2026Mar 31, 2026-$56.94M–
Q4 FY2025Dec 31, 2025-$36.22M–
Q3 FY2025Sep 30, 2025-$38.89M–
Q2 FY2025Jun 30, 2025-$27.96M–
Q1 FY2025Mar 31, 2025-$29.28M–
Q4 FY2024Dec 31, 2024-$20.66M–
Q3 FY2024Sep 30, 2024-$15.92M–
Q2 FY2024Jun 30, 2024-$16.12M–
Q1 FY2024Mar 31, 2024-$26.01M–
Q4 FY2023Dec 31, 2023-$14.65M–
Q3 FY2023Sep 30, 2023-$12.26M–
Q2 FY2023Jun 30, 2023-$10.79M–
Q1 FY2023Mar 31, 2023-$7.99M–

More CG Oncology figures

See a number that looks wrong?